



## AtriCure and Baheal Group Establish Partnership and China Distribution Agreement

June 5, 2018

<< [Back](#) AtriCure and Baheal Group Establish Partnership and China Distribution Agreement

*Baheal will serve as the exclusive distribution partner for AtriCure products across China*

MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure's surgical ablation devices. This new multi-year agreement establishes Baheal as the exclusive distributor for AtriCure, and replaces the company's previous distributor in China.

"We are pleased to have formed this new partnership with Baheal," said Michael Carrel, AtriCure's President and Chief Executive Officer. "With Baheal's stellar reputation, their size and scale, combined with our market-leading devices, we are well positioned to establish a foundation for future growth in China."

AtriCure has been selling its surgical ablation devices in China for the past 14 years. During that time, several of China's leading hospitals have adopted AtriCure devices, and in addition, the company expects to pursue new product approvals over the next several years to eventually bring its full portfolio of surgical ablation and left atrial appendage management devices into the market.

"At Baheal, we're continuously looking for ways to grow and expand our business," said Fu Gang, Chairman of Baheal Pharmaceutical Group. "We believe that there is vast opportunity to treat patients and the market remains underpenetrated, and we're confident that together, we are well positioned to grow and help more patients in China affected by Atrial Fibrillation."

### **About AtriCure, Inc.**

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip Left Atrial Appendage (LAA) Exclusion System products are the most widely sold LAA management devices worldwide, with more than 125,000 implanted to date. For more information, visit [AtriCure.com](http://AtriCure.com) or follow us on Twitter @AtriCure.

### **About Baheal Group**

Founded in 2005, BAHEAL Pharmaceutical Group is a group enterprise devoted to the resource innovation and integration platform in the health industry. Driven by the world's cutting-edge intelligent information technologies, relying on its superb capability in health brand operation and management and building on its highly efficient industry resource integration abilities, the Group has been digging deep in China's medical and health care industry for more than a decade, providing optimized solutions for all links along the big health industry chain through the global brand ecosystem, intelligent application ecosystem, medical service ecosystem and investment ecosystem under its flag.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180605005310/en/>

Source: AtriCure, Inc.

AtriCure, Inc.

Media Relations:

Valerie Storch-Willhaus, 612-605-3311

Senior Director, Corporate Marketing and Communications

[vstorch-willhaus@AtriCure.com](mailto:vstorch-willhaus@AtriCure.com)

or

Investor Relations:

Andy Wade, 513-755-4564

Senior Vice President and Chief Financial Officer

[awade@AtriCure.com](mailto:awade@AtriCure.com)